Patient-Derived Xenograft Models of Human Cancer

1. Front Matter

   Pages i-xi

   PDF

2. Patient-Derived Tumor Xenografts: Historical Background

   • Dong Lin, Xinya Wang, Peter W. Gout, Yuzhuo Wang

   Pages 1-9

3. Towards Best Practice in Establishing Patient-Derived Xenografts

   • Gail P. Risbridger, Mitchell G. Lawrence

   Pages 11-28

4. Fidelity and Stability of PDX Models

   • Gang Li

   Pages 29-42

5. Humanized Mouse and Rat PDX Cancer Models

   • Fallon K. Noto, Tseten Yeshi

   Pages 43-57

6. Studies of Cancer Heterogeneity Using PDX Models

   • Danyi Wen, Feifei Zhang, Yuan Long

   Pages 59-69

7. The Plasticity of Stem-Like States in Patient-Derived Tumor Xenografts

   • Alastair H. Davies, Fraser Johnson, Kirsi Ketola, Amina Zoubeidi

   Pages 71-91

8. Modeling Cancer Metastasis

   • Nora M. Navone, Estefania Labanca

   Pages 93-114

9. Modeling Drug Resistance in PDX Models

   • Erin L. Stewart, Ming Sound Tsao

   Pages 115-126

10. Using PDX for Biomarker Development

    • Werner J. Struss, Peter C. Black

    Pages 127-140

11. Patient-Derived Xenografts as Cancer Models for Preclinical Drug Screening

    • Juliet A. Williams

    Pages 141-154

12. First-Generation Tumor Xenografts: A Link Between Patient-Derived Xenograft Models and Clinical Disease

    • Xin Dong, Peter W. Gout, Lu Yi, Yinhuai Wang, Yong Xu, Kuo Yang

    Pages 155-176

13. Application of PDX Cancer Models in Co-clinical Trials and Personalized/Precision Medicine

    • Hongwei Cheng, Zongwen Liu, Hui Xue, Peter W. Gout, Hong Shan

    Pages 177-192

14. Prospectives

    • Dong Lin, Yuzhuo Wang, Peter W. Gout

    Pages 193-200

15. Back Matter

    Pages 201-204

    PDF

This book provides a comprehensive, state-of-the-art review of PDX cancer models. In separately produced chapters, the history and evolution of PDX models is reviewed, methods of PDX model development are compared in detail, characteristics of available established models are presented, current applications are summarized and new perspectives about use of PDX models are proposed. Each chapter is written by a world-renowned expert who is conducting cutting-edge research in the field. Each of the subsections provide a comprehensive review of existing literature addressing the particular topic followed by a conclusive paragraph detailing future directions. Extensive illustrations make this an interactive text. 


Patient-Derived Xenograft Models of Human Cancer will serve as a highly useful resource for researchers and clinicians dealing with, or interested in, this important topic. It will provide a concise yet comprehensive summary of the currentstatus of the field that will help guide preclinical and clinical applications as well as stimulate investigative efforts. This book will propagate innovative concepts and prompt the development of ground-breaking technological solutions in this field.

• PDX cancer models
• cancer heterogeneity
• Modeling cancer metastasis
• Modeling drug resistance
• PDX and biomarker development

• Department of Urologic Sciences, University of British Columbia, Vancouver, Canada

  Yuzhuo Wang

• Department of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, Canada

  Dong Lin

• Living Tumor Laboratory, BC Cancer Agency/Vancouver Prostate Centre, Vancouver, Canada

  Peter W. Gout

Yuzhuo Wang, PhD
Director, Living Tumor Laboratory
Distinguished Scientist, BC Cancer Agency
Senior Scientist, Vancouver Prostate Centre
Professor, University of British Columbia
675 West 10th Avenue, Room 3.122
Vancouver, BC, Canada V5Z 1L3




Dong Lin, PhD, MD
Research Pathologist, Living Tumor Laboratory

Peter W. Gout, PhD
Scientific Consultant, Living Tumor Laboratory
Honorary Associate Professor, Department of Urologic Sciences, University of British Columbia
Emeritus Senior Scientist, Department of Experimental Therapeutics, BC Cancer Agency
<675 West 10th Avenue, Room 5.108Vancouver, BC, Canada V5Z 1L3

Policies and ethics